Our Values Code of Conduct Audit and Risk Management Innovation and Development Corporate Governance and Nomination Human Resources and Remuneration COMPANY SECRETARY GLOBAL LEADERSHIP TEAM CEO & MANAGING DIRECTOR Collaboration Superior Performance Innovation Integrity Patient Focus Board Committees Key Stakeholders, including Shareholders Board Board composition At the date of this report, there are ten Directors on the Board, comprising nine independent Non-executive Directors and one Executive Director. Throughout the year, there was a maximum of eleven Directors on the Board. Since 1 July 2025 to the date of this report, the following changes to directorships occurred: • Dr Megan Clark and Ms Marie McDonald retired from the Board as Non-executive Directors at the conclusion of the 2025 Annual General Meeting, held on 28 October 2025. • Mr Cameron Price was appointed to the Board as a Non-executive Director effective 1 October 2025. • Mr Gordon Naylor was appointed to the Board as a Non-executive Director effective 1 December 2025. • Mr Costa Saroukos was appointed to the Board as a Non-executive Director effective 1 December 2025. • Dr Paul McKenzie retired from the Board as an Executive Director on 10 February 2026. • Mr Gordon Naylor became an Executive Director on 11 February 2026 when he was appointed Interim CEO and Managing Director. The Board is focused on maintaining an appropriate mix of skills and diversity in its membership. This includes a range of skills, experience and background in the pharmaceutical industry, international business, finance and accounting, and management. In addition to this, CSL took into consideration the skills that are required to deliver on CSL’s future strategy including sustainability. A matrix of Board skills is available in CSL’s FY2026 Corporate Governance Statement available at CSL.com. + R EAD MORE AT WE-ARE-CSL/ CORPORATE-GOVERNANCE 41 CSL Limited Annual Report 2025/26
RkJQdWJsaXNoZXIy MjE2NDg3